TWD
RNA icon

True Wealth Design’s Atrium Therapeutics RNA Stock Holding History

True Wealth Design’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$340 Sell
41
-172
-81% -$2.03K ﹤0.01% 2234
2026
Q2 		$2.86K Buy
213
+212
+21,200% +$2.77K ﹤0.01% 1553
2026
Q1 		$14 Buy
+1
New +$14 ﹤0.01% 2659

Other funds holding RNA

TC
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

True Wealth Design's RNA Position: Q3 2026 in Review

True Wealth Design reduced its Atrium Therapeutics (RNA) stake by 81% in Q3 2026, selling an estimated $2.03K and leaving 41 shares worth $340. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

True Wealth Design first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.86K in Q2 2026. 9 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • True Wealth Design held 41 shares of Atrium Therapeutics worth $340 as of Q3 2026.
  • True Wealth Design sold 172 Atrium Therapeutics shares in Q3 2026, an estimated $2.03K.
  • Atrium Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #2234 holding.
  • True Wealth Design first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • True Wealth Design's Atrium Therapeutics position peaked at $2.86K in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.